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Summary
Background: Although there has been an intense debate whether concomitant use of proton-
pump inhibitors (PPIs) attenuates the antiplatelet effects of thienopyridine derivatives, the
drug—drug interaction remains unclear in Japanese patients with coronary artery disease.
Methods and results: Platelet function test was performed in 461 patients who were sched-
uled for or had undergone stent implantation, treated with 100mg/day of aspirin and a
thienopyridine (200mg/day of ticlopidine or 75mg/day of clopidogrel) for at least 14 days.
Adenosine diphosphate-induced platelet aggregation was evaluated with screen ﬁltration pres-
sure method, and the upper quartile of high platelet reactivity was deﬁned as high on-treatment
platelet reactivity (HPR). PPI use was at physician’s discretion. Patients taking a thienopyridine
plus a PPI (n = 166) were older and had a higher incidence of acute coronary syndromes on admis-
sion compared with patients taking a thienopyridine without a PPI (n = 295). The rate of HPR
was higher in patients taking a thienopyridine plus a PPI than in patients taking a thienopyridine
without a PPI (31% vs 21%, p = 0.01). On multivariate logistic regression analysis, independent
predictors of HPR were concomitant PPI use [odds ratio (OR): 1.66, 95% conﬁdence interval (CI):
1.03—2.68], diabetes mellitus (OR: 1.76, CI: 1.11—2.81), and calcium channel blockers use (OR:
1.93, CI: 1.18—3.18). However, there was no signiﬁcant difference in the rate of extremely high
platelet reactivity [58 patients (12.5%) with PATI < 4.0M] between patients treated with a
thienopyridine plus a PPI and those without a PPI (14% vs 11%, NS).
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Conclusion: HPR was frequently observed in Japanese patients treated with thienopyridines plus
PPIs compared to those without P
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p = 0.01), anemia (52% vs 43%, p < 0.01), and previous gastro-
duodenal ulcer (14% vs 4%, p < 0.01) compared with patients
taking a thienopyridine without a PPI (n = 295). There wereof adverse cardiovascular ev
© 2011 Japanese College of C
ntroduction
hienopyridine derivatives in addition to aspirin have
ecome a cornerstone of medical treatment for patients
ho have acute coronary syndromes (ACS) and/or receive
tent implantation [1—3]. Both ticlopidine and clopidogrel
re prodrugs which must be metabolized by the cytochrome
(CYP) 450 enzyme system to generate their active metabo-
ites [4]. Individual variability in the response of platelets
o thienopyridine derivative treatment might be partially
elated to the level of activation of the CYP450.
Although a prescription of a proton-pump inhibitor (PPI) is
ecommended to minimize the risk of gastrointestinal bleed-
ng complications in all patients receiving dual antiplatelet
herapy [5], several studies showed that PPIs attenuated the
ntiplatelet effects [6—9] and clinical efﬁcacy of clopidogrel
10,11]. These concerns are attributed to the competitive
nhibition of CYP2C19 by PPIs, which is involved in the
etabolic activation of clopidogrel. Moreover, a reduced
unction of CYP2C19 is associated with a reduced response
o clopidogrel and increased risk of adverse cardiovascu-
ar events [12—16]. By contrast, recent studies showed no
ncrease in the risk of cardiovascular events in patients tak-
ng clopidogrel plus PPIs [17—19]. With these conﬂicting
ata, the clopidogrel—PPIs interaction remains unclear. We
etrospectively assessed the impact of concomitant use of
PIs on platelet reactivity in patients who were scheduled
or or had undergone elective stent implantation and had
eceived chronic dual antiplatelet therapy.
ethods
atients
etween June 2006 and December 2009, platelet function
est was performed in 461 patients with coronary artery dis-
ase (363 men; mean age, 68 years), who were scheduled
or or had undergone stent implantation. All study patients
ere on chronic dual antiplatelet therapy with 100mg/day
f aspirin and a Japanese standard dose of thienopyri-
ine derivatives (200mg/day of ticlopidine or 75mg/day
f clopidogrel) for at least 14 days. Thienopyridines and
ntacids were prescribed at each doctor’s discretion. We
xcluded patients with oral anticoagulant agents, or a base-
ine hemoglobin level of <8 g/dl or a platelet count of
100,000/mm3. The study protocol was approved by the
thics committee of Yokohama City University. Written com-
rehensive informed consent was obtained from all patients.
aboratory analysesn the early morning, peripheral venous blood samples were
rawn using a 21G needle and added to a test tube contain-
ng a ﬁnal concentration of 0.313% sodium citrate. Whole
n
t
w
a
PPIs. Further prospective studies are needed to estimate the risk
associated with concomitant use of PPIs and thienopyridines.
ology. Published by Elsevier Ltd. All rights reserved.
lood samples were kept at room temperature for 1 h,
nd thereafter platelet aggregation activity in response to
denosine diphosphate was measured by the screen ﬁltra-
ion pressure method with WBA-neo® (ISK, Tokyo, Japan).
ggregation reactions were started by adding 4 or 5 differ-
nt concentrations of adenosine diphosphate (2, 4, 8, 16,
nd 32M if needed) to whole blood in test tubes, while con-
tantly stirring at 37 ◦C. Five minutes after stimulation, the
bsorbing pressure was measured through a micro-sieve with
0m× 30m holes. The estimated adenosine diphosphate
oncentration resulting in 50% ﬁlter blockage by platelet
ggregation was calculated and deﬁned as the platelet
ggregation threshold index (PATI) [20,21]. Unfortunately,
here is no consensus on the deﬁnition of high on-treatment
latelet reactivity (HPR) derived by this method. Because
hienopyridine responsiveness is normally distributed [22],
nd HPR was deﬁned as the upper quartile of high platelet
eactivity in some previous studies [23—26], the ﬁrst quartile
as deﬁned as HPR in the present study.
Renal insufﬁciency was deﬁned as an estimated glomeru-
ar ﬁltration rate of <60mL/min/1.73m2. Anemia was
eﬁned as a baseline hemoglobin level of <13 g/dl in men
nd <12 g/dl in women.
tatistical analysis
ategorical variables were reported as percentages and
ompared by the chi-square test. Continuous variables were
eported as means± SD or median (interquartile range) and
ompared by Student’s t-test. Potential predictors with
-values of <0.20 on univariate analysis which were demo-
raphic, clinical, and medicinal variables were included in
ultivariate logistic regression analysis. Odds ratios (OR)
nd 95% conﬁdence intervals (CI) were calculated. p-Values
f <0.05 were considered to indicate statistical signiﬁcance.
ata were analyzed with SPSS 17 (SPSS, Inc., Chicago, IL,
SA).
esults
atient characteristics
atients taking a thienopyridine plus a PPI (n = 166) were
lder (69± 9 vs 67± 10 years, p = 0.01) and had a lower
ncidence of hypertension (62% vs 74%, p < 0.01), and had a
igher incidence of ACS on admission (23% vs 13%, p < 0.01),
rior coronary artery bypass graft surgery (11% vs 5%,o signiﬁcant differences in the other baseline characteris-
ics between the 2 groups (Table 1A) Among patients treated
ith clopidogrel, higher percentage of ACS on admission
nd lower percentage of hypertension were observed in
PI users than in non-PPI users. Among patients treated
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Table 1A Patient characteristics.
Thienopyridines + PPIs
(n = 166)
Thienopyridines without
PPIs (n = 295)
p-Value
Age (yrs) 69± 9 67± 10 0.01
Male gender 81% 77% 0.30
Body mass index (kg/m2) 23.7± 3.7 24.1± 3.3 0.22
Hypertension 62% 74% <0.01
Diabetes mellitus 44% 40% 0.44
Hypercholesterolemia (>220mg/dl) 63% 65% 0.60
Current smoker 42% 38% 0.44
Acute coronary syndrome on admission 23% 13% <0.01
Prior myocardial infarction 42% 39% 0.63
Prior coronary artery bypass surgery 11% 5% 0.01
Old cerebral infarction 10% 11% 0.60
Peripheral artery disease 14% 16% 0.60
Renal insufﬁciencya 58% 55% 0.49
Anemiab 52% 43% <0.01
Previous gastroduodenal ulcer 14% 4% <0.01
3 vessel disease 29% 26% 0.58
Drug-eluting stent use 80% 76% 0.33
Values are percentages or means± SDs.
a Renal insufﬁciency was deﬁned as estimated glomerular ﬁltration rate <60mL/min/1.73m2. PPIs, proton pump inhibitors.
b Anemia was deﬁned as baseline hemoglobin <13 g/dl in men and <12 g/dl in women.
Table 1B Patient characteristics.
Clopidogrel + PPIs
(n = 49)
Clopidogrel
without PPIs
(n = 93)
p-Value Ticlopidine + PPIs
(n = 117)
Ticlopidine
without PPIs
(n = 202)
p-Value
Age (yrs) 69± 10 67± 10 0.35 69± 9 67± 9 0.02
Male gender 78% 75% 0.76 83% 78% 0.31
Body mass index (kg/m2) 23.7± 3.8 24.1± 3.5 0.51 23.7± 3.6 24.1± 3.2 0.30
Hypertension 49% 73% <0.01 68% 74% 0.19
Diabetes mellitus 43% 40% 0.72 44% 41% 0.50
Hypercholesterolemia
(>220mg/dl)
65% 62% 0.72 62% 66% 0.38
Current smoker 51% 37% 0.09 38% 39% 0.85
Acute coronary syndrome on
admission
31% 12% <0.01 20% 13% 0.10
Prior myocardial infarction 31% 40% 0.28 46% 39% 0.21
Prior coronary artery bypass
surgery
10% 6% 0.42 12% 4% 0.01
Old cerebral infarction 6% 15% 0.11 11% 9% 0.62
Peripheral artery disease 16% 16% 0.97 14% 16% 0.52
Renal insufﬁciencya 55% 49% 0.52 59% 57% 0.72
Anemiab 57% 45% 0.17 50% 42% 0.19
Previous gastroduodenal ulcer 8% 8% 0.87 16% 2% 0.01
3 vessel disease 38% 23% 0.17 25% 28% 0.70
Drug-eluting stent use 71% 82% 0.15 83% 73% 0.03
Values are percentages or means± SDs.
ion ra
d <1a Renal insufﬁciency was deﬁned as estimated glomerular ﬁltrat
b Anemia was deﬁned as baseline hemoglobin <13 g/dl in men anwith ticlopidine, PPI users were more likely to be older
and have drug-eluting stent implantation and prior coronary
artery bypass graft surgery compared with non-PPI users
(Table 1B).
B
A
fte <60mL/min/1.73m2. PPIs, proton pump inhibitors.
2 g/dl in women.aseline medications
ll study patients had received dual antiplatelet therapy
or at least 14 days before platelet aggregation test. The
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Table 2 Baseline medications.
Thienopyridines + PPIs
(n = 166)
Thienopyridines
without PPIs
(n = 295)
p-Value
Thienopyridine derivatives
Ticlopidine 70% 68% 0.65
Clopidogrel 30% 32% 0.65
Duration of thienopyridine use before sampling (days) 242 (28, 361) 303 (37, 370) 0.42
Other agents
Calcium-channel blockers 28% 46% <0.01
Beta-blockers 73% 70% 0.48
ACE inhibitors or Angiotensin II receptor blockers 70% 77% 0.09
Statins 87% 85% 0.56
Antidiabetic agents 34% 38% 0.40
H2-receptor antagonists 0% 34% <0.01
PPIs
Omeprazole 34% 0% <0.01
Lansoprazole 36% 0% <0.01
Rabeprazole 30% 0% <0.01
Values are percentages or median (interquartile range). ACE, angioten
median duration of thienopyridine use before sampling was
similar between patients taking a thienopyridine plus a PPI
and patients taking a thienopyridine without a PPI [242
(28, 361) vs 303 (37, 370) days, p = 0.42]. However, the
incidences of taking calcium-channel blockers (28% vs 46%,
p < 0.01) and H2-receptor antagonists (0% vs 34%, p < 0.01)
were lower in patients taking a thienopyridine plus a PPI
than in those taking a thienopyridine without a PPI, the per-
centages of patients who were receiving other agents were
similar between the groups (Table 2). All patients continued
to receive aspirin during thienopyridine treatment.
Incidence of low-responders
Fig. 1 shows the distribution of PATI in patients taking
thienopyridines plus PPIs and in patients taking thienopy-
ridines without PPIs. Although the percentage of patients
with PATI of 4—8M was highest in patients taking a
Figure 1 Distribution of the platelet aggregation threshold
index (PATI) in patients taking thienopyridines plus proton pump
inhibitors (PPIs) and in patients taking thienopyridines without
PPIs. PATI was determined by platelet aggregation activity in
response to adenosine diphosphate using the screen ﬁltration
pressure method.
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hienopyridine plus a PPI, PATI of 8—16M was most fre-
uently observed in those taking a thienopyridine without
PPI. All subjects were classiﬁed into 2 groups according
o the extent of residual platelet reactivity; the ﬁrst quar-
ile group (PATI <6.6M) was classiﬁed as HPR (n = 115).
he rate of HPR tended to be higher in patients treated
ith clopidogrel than in those with ticlopidine (30% vs 23%,
= 0.07). HPR was more frequently observed in patients
reated with a thienopyridine plus a PPI compared to those
ithout a PPI (31% vs 21%, p = 0.01) (Fig. 2A). A similar trend
f thienopyridine—PPI interaction was found in both patients
aking clopidogrel and those taking ticlopidine (Fig. 2B, C).
n multivariate logistic regression analysis, concomitant use
f PPIs was an independent predictor of HPR (OR: 1.66, CI:
.03—2.68, p = 0.03), in addition to diabetes mellitus (OR:
.76, CI: 1.11—2.81), and calcium-channel blockers use (OR:
.93, CI: 1.18—3.18). ACS on admission was not an indepen-
ent predictor (OI: 1.55, CI: 0.78—12.86, p = 0.16) (Table 3).
Although the incidence of moderately high platelet reac-
ivity [58 patients (12.5%) with PATI of 4.0—6.6M] was
igher in patients treated with a thienopyridine plus a PPI
han in those without a PPI (17% vs 10%, p = 0.01), there
as no signiﬁcant difference in the rate of extremely high
latelet reactivity [58 patients (12.5%) with PATI <4.0M]
etween the groups (14% vs 11%, NS) (Fig. 2A).
There was no signiﬁcant difference in the incidence of
PR among 56 patients treated with omeprazole (27%), 59
ith lansoprazole (34%), and 50 with rabeprazole (30%). In
ddition, the incidence of HPR tended to be higher in 165
atients treated with PPIs than that in 99 patients treated
ith H2-receptor antagonists and that in 196 patients who
ere not treated with either agents (31% vs 23%, 21%,
= 0.11). Use of H2-receptor antagonists, another option for
rophylaxis of gastrointestinal injury, is not associated with
he percentage of HPR in patients receiving dual antiplatelet
herapy.
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Figure 2 Incidence of high on-treatment platelet reactivity in patients taking thienopyridines plus proton pump inhibitors (PPIs)
and patients taking thienopyridines without PPIs (A), in patients taking clopidogrel plus PPIs and patients taking clopidogrel without
PPIs (B), and in patients taking ticlopidine plus PPIs and patients taking ticlopidine without PPIs (C). PATI, platelet aggregation
threshold index.
Table 3 Predictors of low-responsiveness to antiplatelet therapy*.
OR (95% CI) p-Value
Calcium-channel blockers use 1.93 (1.18—3.18) 0.01
Diabetes mellitus 1.76 (1.11—2.81) 0.01
Proton pump inhibitors use 1.66 (1.03—2.68) 0.03
Anemia 1.60 (0.98—2.62) 0.05
Acute coronary syndrome on admission 1.52 (0.78—12.86) 0.16
* Low-responsiveness to antiplatelet therapy was deﬁned as the upper quartile of high platelet reactivity evaluated by adenosine
press
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gdiphosphate-induced platelet aggregation with screen ﬁltration
predictors with p-values of <0.20 on univariate analysis, shown
variables, were included in a multivariate logistic regression anal
Discussion
PPIs are preferred agents for prophylaxis of gastroin-
testinal injury in all patients receiving dual antiplatelet
therapy [5,27]. Although it is suggested that PPIs are asso-
ciated with lower platelet inhibition of clopidogrel [6—8],
there are no convincing randomized clinical trial data for
the clopidogrel—PPI interaction except for COGENT [28].
However, although the CYP2C19 genetic variant is often
seen in the Japanese population [29], few studies have
examined the drug—drug interaction in Japanese patients
who had received dual antiplatelet therapy and PPIs. We
assessed the impact of concomitant use of PPIs on adeno-
sine diphosphate-induced platelet aggregation in patients
i
a
fure method. OR, odds ratio; CI, conﬁdence interval. Potential
bles 1 and 2 which were demographic, clinical, and medicinal
ith chronic dual antiplatelet therapy who were scheduled
or or had undergone elective stent implantation. In the
resent study, HPR was frequently observed in Japanese
atients treated with a thienopyridine plus a PPI com-
ared to those without a PPI. Furthermore, on multivariate
ogistic regression analysis, the combination of a thienopy-
idine plus a PPI was associated with HPR. Nevertheless,
here was no signiﬁcant difference in the rate of extremely
igh platelet reactivity with (PATI <4.0M) between the 2
roups.
Similarly to most of all previous platelet function stud-
es [6—9], the combination of thienopyridine plus PPIs was
ssociated with HPR in the present study. However, the dif-
erence was mainly driven by the incidence of patients with
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Update) and ACC/AHA/SCAI Guidelines on Percutaneous Coro-
nary Intervention (updating the 2005 Guideline and 200780
oderately high platelet reactivity (PATI of 4.0—6.6M).
hat is the reason that concomitant use of PPIs and
hienopyridine derivatives is not related to a higher rate of
xtremely high platelet reactivity? First, antiplatelet effect
f thienopyridines was not completely diminished even in
PI treatment. The OCLA study showed statistically sig-
iﬁcant but modest attenuation with wide dispersion of
he vasodilator-stimulated phosphoprotein (VASP) index in
atients treated with omeprazole in addition to clopidogrel,
ompared with that in the clopidogrel plus placebo group
6]. Another reason may be CYP2C19 loss-of-function poly-
orphisms. It was reported that CYP2C19 polymorphisms
nd HPR on clopidogrel therapy were more frequent in
ast Asians compared with Caucasians [29—32]. A recent
tudy showed that the additional attenuation of antiplatelet
ffect was not strongly inﬂuenced by concomitant use of
PIs in patients with CYP2C19 polymorphisms [33]. Calcium-
hannel blockers inhibit CYP3A4 and reduce the conversion
f clopidogrel to its active metabolite [34]. Use of calcium-
hannel blockers is one of the predictive factors of HPR,
hown by multivariate analysis in the present study. The
ssociation of concomitant use of calcium-channel blockers
ith the reduced antiplatelet effects of clopidogrel was also
ound in some reports [35,36].
Previous studies have reported that patients with HPR
ho receive clopidogrel therapy and undergo elective per-
utaneous coronary intervention (PCI) are at increased risk
or post-procedural ischemic events, and HPR is an inde-
endent predictor of stent thrombosis [24,26,37—39]. Some
revious observational studies demonstrated the association
f concomitant use of clopidogrel and PPIs with a worse
linical outcome [10,11]. These results suggested the cor-
elation of the poor clopidogrel response with thrombotic
vents. On the other hand, analysis of propensity-matched
r randomized trial participants showed no signiﬁcant asso-
iation [17,18,28,40]. Thrombotic events after PCI are
ulti-factorial clinical phenomena, and HPR is just one of
hese risk factors. Moreover, registries showed that stent
hrombosis occurred less frequently in Japanese patients
han in Caucasian patients [41—43]. Therefore, it seems that
he drug—drug interaction may have little impact on seri-
us threat for low-risk Japanese patients. However, most
ggregation studies showed that PPIs attenuate the effect
f clopidogrel to some degree [6—9]. At least, PPIs should
e cautiously prescribed in patients who are at the highest
isk of thrombosis including ST-segment elevation myocar-
ial infarction or undergoing emergent PCI.
Both ticlopidine and clopidogrel are metabolized to
enerate their active metabolites by the CYP 450
nzyme system including CYP2C19. Responsiveness to either
00mg/day of ticlopidine or 75mg/day of clopidogrel fol-
ows a normal distribution with similar rates of HPR in
aucasian patients [22]. A recent study demonstrated that
he safety/tolerability of clopidogrel is superior to that of
iclopidine [44,45]; therefore, physicians might prefer clopi-
ogrel to ticlopidine. In the present study, the incidence of
PR tended to be higher in patients treated with 75mg/day
f clopidogrel compared with those with 200mg/day of
iclopidine. Considering our data, a standard dose of clopi-
ogrel may be inadequate to inhibit enhanced platelet
eactivity in some Japanese patients undergoing coronary
tenting.K. Tsukahara et al.
tudy limitations
he present study has several limitations. It is retrospec-
ively performed and has a relatively small sample size of
study population. Another limitation was that the major-
ty of subjects received ticlopidine, because clopidogrel is
pproved for use in only patients with non-ST elevation ACS
n Japan. However, a similar trend of thienopyridine—PPI
nteraction was found in both patients taking clopido-
rel and those taking ticlopidine. Moreover, we obtained
o data on CYP2C19 polymorphisms. In addition, we only
ssessed platelet aggregation activity in response to adeno-
ine diphosphate on thienopyridine treatment at one time
oint by a single method with WBA-neo®. Furthermore, we
id not evaluate the impact of PPI use on the platelet
eactivity in patients taking aspirin without thienopyridine
erivatives as a control group. However, mean value of PATI
as 2.6± 1.1M (from 1.1 to 5.1M) in 31 patients with
table coronary artery disease who were taking 100mg/day
f aspirin for at least 14 days without thienopyridines
nd PPIs. This result showed that all patients treated
ith aspirin monotherapy had PATI <6.6M, which corre-
ponded to HPR to thienopyridine treatment in the present
tudy. Finally, high-risk patients with ST-segment eleva-
ion myocardial infarction or undergoing emergent PCI were
ot included. Regardless of these limitations, the present
tudy demonstrated that PPI administration was associated
ith reduced platelet response to chronic thienopyridine
reatment, though it was suggested that the drug—drug
nteraction might be modest.
onclusions
PR was frequently observed in Japanese patients treated
ith thienopyridines plus PPIs compared to those without
PIs. On multivariate logistic regression analysis, the com-
ination of thienopyridines plus PPIs was associated with
PR. Further prospective studies are needed to estimate
he risk of adverse cardiovascular events associated with
oncomitant use of PPIs and thienopyridines.
eferences
[1] Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK.
Effects of clopidogrel in addition to aspirin in patients with
acute coronary syndromes without ST-segment elevation. N
Engl J Med 2001;345:494—502.
[2] Steinhubl SR, Berger PB, Mann III JT, Fry ET, DeLago A, Wilmer
C, Topol EJ. Early and sustained dual oral antiplatelet therapy
following percutaneous coronary intervention: a randomized
controlled trial. JAMA 2002;288:2411—20.
[3] Kushner FG, Hand M, Smith Jr SC, King III SB, Anderson JL,
Antman EM, Bailey SR, Bates ER, Blankenship JC, Casey Jr
DE, Green LA, Hochman JS, Jacobs AK, Krumholz HM, Mor-
rison DA, et al. 2009 Focused Updates: ACC/AHA Guidelines
for the Management of Patients With ST-Elevation Myocar-
dial Infarction (updating the 2004 Guideline and 2007 FocusedFocused Update): a report of the American College of Car-
diology Foundation/American Heart Association Task Force on
Practice Guidelines. Circulation 2009;120:2271—306.
ne d
[
[
[
[
[
[
[
[
[
[
[
[
[
[Concomitant use of proton-pump inhibitors and thienopyridi
[4] Hulot JS, Bura A, Villard E, Azizi M, Remones V, Goyenvalle C,
Aiach M, Lechat P, Gaussem P. Cytochrome P450 2C19 loss-of-
function polymorphism is a major determinant of clopidogrel
responsiveness in healthy subjects. Blood 2006;108:2244—7.
[5] Bhatt DL, Scheiman J, Abraham NS, Antman EM, Chan
FK, Furberg CD, Johnson DA, Mahaffey KW, Quigley EM.
ACCF/ACG/AHA 2008 expert consensus document on reduc-
ing the gastrointestinal risks of antiplatelet therapy and NSAID
use: a report of the American College of Cardiology Foundation
Task Force on Clinical Expert Consensus Documents. Circulation
2008;118:1894—909.
[6] Gilard M, Arnaud B, Cornily JC, Le Gal G, Lacut K, Le Calvez
G, Mansourati J, Mottier D, Abgrall JF, Boschat J. Inﬂuence of
omeprazole on the antiplatelet action of clopidogrel associated
with aspirin: the randomized, double-blind OCLA (Omeprazole
CLopidogrel Aspirin) study. J Am Coll Cardiol 2008;51:256—60.
[7] Small DS, Farid NA, Payne CD, Weerakkody GJ, Li YG, Brandt
JT, Salazar DE, Winters KJ. Effects of the proton pump inhibitor
lansoprazole on the pharmacokinetics and pharmacodynamics
of prasugrel and clopidogrel. J Clin Pharmacol 2008;48:475—84.
[8] Sibbing D, Morath T, Stegherr J, Braun S, Vogt W, Hadamitzky M,
Schomig A, Kastrati A, von Beckerath N. Impact of proton pump
inhibitors on the antiplatelet effects of clopidogrel. Thromb
Haemost 2009;101:714—9.
[9] Zuern CS, Geisler T, Lutilsky N, Winter S, Schwab M, Gawaz
M. Effect of comedication with proton pump inhibitors (PPIs)
on post-interventional residual platelet aggregation in patients
undergoing coronary stenting treated by dual antiplatelet ther-
apy. Thromb Res 2010;125:e51—4.
[10] Ho PM, Maddox TM, Wang L, Fihn SD, Jesse RL, Peterson
ED, Rumsfeld JS. Risk of adverse outcomes associated with
concomitant use of clopidogrel and proton pump inhibitors
following acute coronary syndrome. JAMA 2009;301:937—
44.
[11] Juurlink DN, Gomes T, Ko DT, Szmitko PE, Austin PC, Tu JV,
Henry DA, Kopp A, Mamdani MM. A population-based study
of the drug interaction between proton pump inhibitors and
clopidogrel. CMAJ 2009;180:713—8.
[12] Simon T, Verstuyft C, Mary-Krause M, Quteineh L, Drouet E,
Meneveau N, Steg PG, Ferrieres J, Danchin N, Becquemont L.
Genetic determinants of response to clopidogrel and cardio-
vascular events. N Engl J Med 2009;360:363—75.
[13] Trenk D, Hochholzer W, Fromm MF, Chialda LE, Pahl A, Valina
CM, Stratz C, Schmiebusch P, Bestehorn HP, Buttner HJ, Neu-
mann FJ. Cytochrome P450 2C19 681G>A polymorphism and
high on-clopidogrel platelet reactivity associated with adverse
1-year clinical outcome of elective percutaneous coronary
intervention with drug-eluting or bare-metal stents. J Am Coll
Cardiol 2008;51:1925—34.
[14] Collet JP, Hulot JS, Pena A, Villard E, Esteve JB, Silvain J, Payot
L, Brugier D, Cayla G, Beygui F, Bensimon G, Funck-Brentano C,
Montalescot G. Cytochrome P450 2C19 polymorphism in young
patients treated with clopidogrel after myocardial infarction:
a cohort study. Lancet 2009;373:309—17.
[15] Mega JL, Close SL, Wiviott SD, Shen L, Hockett RD, Brandt JT,
Walker JR, Antman EM, Macias W, Braunwald E, Sabatine MS.
Cytochrome p-450 polymorphisms and response to clopidogrel.
N Engl J Med 2009;360:354—62.
[16] Shuldiner AR, O’Connell JR, Bliden KP, Gandhi A, Ryan K,
Horenstein RB, Damcott CM, Pakyz R, Tantry US, Gibson
Q, Pollin TI, Post W, Parsa A, Mitchell BD, Faraday N, et
al. Association of cytochrome P450 2C19 genotype with the
antiplatelet effect and clinical efﬁcacy of clopidogrel therapy.
JAMA 2009;302:849—57.
[17] O’Donoghue ML, Braunwald E, Antman EM, Murphy SA, Bates
ER, Rozenman Y, Michelson AD, Hautvast RW, Ver Lee PN, Close
SL, Shen L, Mega JL, Sabatine MS, Wiviott SD. Pharmacody-
namic effect and clinical efﬁcacy of clopidogrel and prasugrel
[erivatives 281
with or without a proton-pump inhibitor: an analysis of two
randomised trials. Lancet 2009;374:989—97.
18] Rassen JA, Choudhry NK, Avorn J, Schneeweiss S. Cardiovas-
cular outcomes and mortality in patients using clopidogrel
with proton pump inhibitors after percutaneous coro-
nary intervention or acute coronary syndrome. Circulation
2009;120:2322—9.
19] Ray WA, Murray KT, Grifﬁn MR, Chung CP, Smalley WE, Hall K,
Daugherty JR, Kaltenbach LA, Stein CM. Outcomes with concur-
rent use of clopidogrel and proton-pump inhibitors: a cohort
study. Ann Intern Med 2010;152:337—45.
20] Ozeki Y, Sudo T, Toga K, Nagamura Y, Ito H, Ogawa T, Kimura Y.
Characterization of whole blood aggregation with a new type of
aggregometer by a screen ﬁltration pressure method. Thromb
Res 2001;101:65—72.
21] Sudo T, Ito H, Ozeki Y, Kimura Y. Estimation of anti-platelet
drugs on human platelet aggregation with a novel whole blood
aggregometer by a screen ﬁltration pressure method. Br J Phar-
macol 2001;133:1396—404.
22] Campo G, Valgimigli M, Gemmati D, Percoco G, Catozzi L, Fran-
gione A, Federici F, Ferrari F, Tebaldi M, Luccarelli S, Parrinello
G, Ferrari R. Poor responsiveness to clopidogrel: drug-speciﬁc
or class-effect mechanism? Evidence from a clopidogrel-
to-ticlopidine crossover study. J Am Coll Cardiol 2007;50:
1132—7.
23] Matetzky S, Shenkman B, Guetta V, Shechter M, Bienart R,
Goldenberg I, Novikov I, Pres H, Savion N, Varon D, Hod H. Clopi-
dogrel resistance is associated with increased risk of recurrent
atherothrombotic events in patients with acute myocardial
infarction. Circulation 2004;109:3171—5.
24] Gurbel PA, Bliden KP, Guyer K, Cho PW, Zaman KA, Kreutz
RP, Bassi AK, Tantry US. Platelet reactivity in patients and
recurrent events post-stenting: results of the PREPARE POST-
STENTING Study. J Am Coll Cardiol 2005;46:1820—6.
25] Hochholzer W, Trenk D, Bestehorn HP, Fischer B, Valina CM,
Ferenc M, Gick M, Caputo A, Buttner HJ, Neumann FJ. Impact
of the degree of peri-interventional platelet inhibition after
loading with clopidogrel on early clinical outcome of elective
coronary stent placement. J Am Coll Cardiol 2006;48:1742—50.
26] Cuisset T, Frere C, Quilici J, Barbou F, Morange PE, Hov-
asse T, Bonnet JL, Alessi MC. High post-treatment platelet
reactivity identiﬁed low-responders to dual antiplatelet ther-
apy at increased risk of recurrent cardiovascular events after
stenting for acute coronary syndrome. J Thromb Haemost
2006;4:542—9.
27] Hokimoto S, Matsui K, Oshima S, Noda K, Kaikita K, Sum-
ida H, Sugiyama S, Ogawa H. Effects of gastric medicines on
gastroduodenal injury in patients with stable angina during
antiplatelet therapy. J Cardiol 2009;54:71—5.
28] Bhatt DL, Cryer BL, Contant CF, Cohen M, Lanas A, Schnitzer
TJ, Shook TL, Lapuerta P, Goldsmith MA, Laine L, Scirica BM,
Murphy SA, Cannon CP. Clopidogrel with or without omeprazole
in coronary artery disease. N Engl J Med 2010;363:1909—17.
29] Jinnai T, Horiuchi H, Makiyama T, Tazaki J, Tada T, Akao M,
Ono K, Hoshino K, Naruse Y, Takahashi K, Watanabe H, Kita T,
Kimura T. Impact of CYP2C19 polymorphisms on the antiplatelet
effect of clopidogrel in an actual clinical setting in Japan. Circ
J 2009;73:1498—503.
30] Desta Z, Zhao X, Shin JG, Flockhart DA. Clinical signiﬁcance of
the cytochrome P450 2C19 genetic polymorphism. Clin Phar-
macokinet 2002;41:913—58.
31] Lee JM, Park S, Shin DJ, Choi D, Shim CY, Ko YG, Kim JS,
Shin ES, Chang CW, Lee JE, Jang Y. Relation of genetic poly-
morphisms in the cytochrome P450 gene with clopidogrel
resistance after drug-eluting stent implantation in Koreans. Am
J Cardiol 2009;104:46—51.
32] Price MJ, Nayak KR, Barker CM, Kandzari DE, Teirstein PS.
Predictors of heightened platelet reactivity despite dual-
2[
[
[
[
[
[
[
[
[
[
[
[
[82
antiplatelet therapy in patients undergoing percutaneous
coronary intervention. Am J Cardiol 2009;103:1339—43.
33] Hulot JS, Wuerzner G, Bachelot-Loza C, Azizi M, Blanchard
A, Peyrard S, Funck-Brentano C, Gaussem P. Effect of an
increased clopidogrel maintenance dose or lansoprazole co-
administration on the antiplatelet response to clopidogrel
in CYP2C19-genotyped healthy subjects. J Thromb Haemost
2010;8:610—3.
34] Lau WC, Gurbel PA, Watkins PB, Neer CJ, Hopp AS, Carville
DG, Guyer KE, Tait AR, Bates ER. Contribution of hepatic
cytochrome P450 3A4 metabolic activity to the phenomenon
of clopidogrel resistance. Circulation 2004;109:166—71.
35] Siller-Matula JM, Lang I, Christ G, Jilma B. Calcium-channel
blockers reduce the antiplatelet effect of clopidogrel. J Am
Coll Cardiol 2008;52:1557—63.
36] Gremmel T, Steiner S, Seidinger D, Koppensteiner R, Panzer
S, Kopp CW. Calcium-channel blockers decrease clopidogrel-
mediated platelet inhibition. Heart 2010;96:186—9.
37] Buonamici P, Marcucci R, Migliorini A, Gensini GF, Santini A,
Paniccia R, Moschi G, Gori AM, Abbate R, Antoniucci D. Impact
of platelet reactivity after clopidogrel administration on drug-
eluting stent thrombosis. J Am Coll Cardiol 2007;49:2312—7.
38] Bliden KP, DiChiara J, Tantry US, Bassi AK, Chaganti SK, Gurbel
PA. Increased risk in patients with high platelet aggregation
receiving chronic clopidogrel therapy undergoing percutaneous
coronary intervention: is the current antiplatelet therapy ade-
quate? J Am Coll Cardiol 2007;49:657—66.
39] Tsukahara K, Kimura K, Morita S, Ebina T, Kosuge M, Hibi
K, Okuda J, Iwahashi N, Maejima N, Nakachi T, Ohtsuka
F, Hashiba K, Tahara Y, Sugano T, Umemura S. Impact of
high-responsiveness to dual antiplatelet therapy on bleeding
complications in patients receiving drug-eluting stents. Circ J
2010;74:679—85.K. Tsukahara et al.
40] Hulot JS, Collet JP, Silvain J, Pena A, Bellemain-Appaix A,
Barthelemy O, Cayla G, Beygui F, Montalescot G. Cardiovascular
risk in clopidogrel-treated patients according to cytochrome
P450 2C19*2 loss-of-function allele or proton pump inhibitor
coadministration: a systematic meta-analysis. J Am Coll Car-
diol 2010;56:134—43.
41] Kimura T, Morimoto T, Nakagawa Y, Tamura T, Kadota K,
Yasumoto H, Nishikawa H, Hiasa Y, Muramatsu T, Meguro T,
Inoue N, Honda H, Hayashi Y, Miyazaki S, Oshima S, et al.
Antiplatelet therapy and stent thrombosis after sirolimus-
eluting stent implantation. Circulation 2009;119:987—
95.
42] Ikari Y, Kotani J, Kozuma K, Kyo E, Nakamura M, Yokoi H.
Assessment of sirolimus-eluting coronary stent implantation
with aspirin plus low dose ticlopidine administration: one year
results from CYPHER Stent Japan Post-Marketing Surveillance
Registry (J-PMS). Circ J 2009;73:1038—44.
43] Wenaweser P, Daemen J, Zwahlen M, van Domburg R,
Juni P, Vaina S, Hellige G, Tsuchida K, Morger C, Boersma
E, Kukreja N, Meier B, Serruys PW, Windecker S. Inci-
dence and correlates of drug-eluting stent thrombosis in
routine clinical practice 4-year results from a large 2-
institutional cohort study. J Am Coll Cardiol 2008;52:1134—
40.
44] Hayashi F, Iijima R, Nakamura M, Sugi K. Safety and efﬁcacy of
clopidogrel treatment in Japanese patients undergoing drug-
eluting stent implantation. J Cardiol 2010;55:34—40.
45] Bertrand ME, Rupprecht HJ, Urban P, Gershlick AH. Double-
blind study of the safety of clopidogrel with and without a
loading dose in combination with aspirin compared with ticlo-
pidine in combination with aspirin after coronary stenting: the
clopidogrel aspirin stent international cooperative study (CLAS-
SICS). Circulation 2000;102:624—9.
